Περιεχόμενα
SECTION 1: IMMUNOLOGY
4 Immune Response in Organ Transplantation
Roshini Sarah Abraham, PhD, D(ABMLI)
8 Regulatory Immune Cells and Transplant Tolerance
Roshini Sarah Abraham, PhD, D(ABMLI)
14 Viral Infections and Immune Response
Roshini Sarah Abraham, PhD, D(ABMLI)
20 Genetics of Complement Defects Associated with Atypical HUS and TMA
Roshini Sarah Abraham, PhD, D(ABMLI)
24 Laboratory-Based Immune Monitoring in Organ Transplantation
Sanya J. Thomas, MD and Roshini Sarah Abraham, PhD, D(ABMLI)
30 Immune Manipulation and Accommodation: Introduction to Xenogenic Transplantation
Roshini Sarah Abraham, PhD, D(ABMLI)
34 Graft Vs. Host Disease in Solid Organ Transplantation
Roshini Sarah Abraham, PhD, D(ABMLI) and Sanya J. Thomas, MD
SECTION 2: HLA TESTING
40 Human Leukocyte Antigen System
Manish J. Gandhi, MD
42 Histocompatibility Testing
Manish J. Gandhi, MD
44 Transplantation and HLA
Manish J. Gandhi, MD
48 ABO Blood Group Antigens and Transplantation
Manish J. Gandhi, MD
50 Apheresis and Transplantation
Manish J. Gandhi, MD
52 HLA and Transfusion
Manish J. Gandhi, MD
SECTION 3: IMMUNOSUPPRESSIVE DRUGS
56 Mechanism of Action of Immunosuppressive Drugs
Loralie Langman, PhD and Florian Lemaitre, PharmaD, PhD
58 Therapeutic Drug Monitoring in Transplant Patients
Loralie Langman, PhD and Florian Lemaitre, PharmaD, PhD
62 History of Immunosuppression Drugs in Transplantation
Loralie Langman, PhD and Florian Lemaitre, PharmaD, PhD
SECTION 4: KIDNEY TRANSPLANTATION
66 History of Kidney Transplantation
Lynn D. Cornell, MD
68 Pathologic Classification of Renal Allograft Diseases
Robert B. Colvin, MD
70 Examination of End-Stage Kidney
Shane Meehan, MB, BCh
76 Evaluation of the End-Stage Kidney
Shane Meehan, MB, BCh
82 Evaluation of Allograft Kidney
Lynn D. Cornell, MD and Evan Farkash, MD, PhD
88 Evaluation of Donor Kidney
Lynn D. Cornell, MD and Evan Farkash, MD, PhD
94 Evaluation of Transplant Nephrectomy
Shane Meehan, MB, BCh and Evan Farkash, MD, PhD
98 Evaluation of Fibrosis
A. Brad Farris, III, MD, MBA
102 Protocol Biopsies
Lynn D. Cornell, MD and Evan Farkash, MD, PhD
106 Accommodation
Lynn D. Cornell, MD
108 Tolerance
Robert B. Colvin, MD
SURGICAL COMPLICATIONS
112 Acute Allograft Ischemia
A. Brad Farris, III, MD, MBA
116 Size Mismatch Allograft Injury
Anthony Chang, MD and Yael K. Heher, MD, MPH, FRCP(C)
118 Urine Leak
A. Brad Farris, III, MD, MBA
119 Lymphocele
A. Brad Farris, III, MD, MBA
120 Multinucleated Endotheliopathy
Jonathan Zuckerman, MD, PhD
124 Transplant Renal Artery Stenosis
A. Brad Farris, III, MD, MBA
126 Tranplant Renal Artery or Vein Thrombosis
A. Brad Farris, III, MD, MBA
128 Kidney Xenografts
Ivy A. Rosales, MD
132 Chronic Antibody-Mediated Rejection
Lynn D. Cornell, MD and Michael Mengel, MD
ALLOGRAF REJECTION
144 Hyperacute Rejection
Lynn D. Cornell, MD and Michael Mengel, MD
148 Acute T-Cell-Mediated Rejection
Lynn D. Cornell, MD and Michael Mengel, MD
158 Chronic T-Cell-Mediated Rejection
Lynn D. Cornell, MD and Michael Mengel, MD
162 Acute Antibody-Mediated Rejection
Lynn D. Cornell, MD and Michael Mengel, MD
170 Transcript Analysis of Renal Transplant Biopsies
Michael Mengel, MD and R. Neal Smith, MD, PhD
RECURRENT AND DE NOVO DISEASES
174 Diseases That Recur in Allografts
Anthony Chang, MD, Lynn D. Cornell, MD, and R. Neal Smith, MD, PhD
180 De Novo Focal Segmental Glomerulosclerosis
Anthony Chang, MD and Astrid Weins, MD, PhD
182 De Novo Membranous Nephropathy
Anthony Chang, MD
186 Anti-GBM Disease in Alport Syndrome
Anthony Chang, MD and R. Neal Smith, MD, PhD
188 Chimerism Transition Syndrome
A. Brad Farris, III, MD, MBA
190 Late Posttransplant Histology
Lynn D. Cornell, MD
KIDNEY PATHOLOGY OF RECIPIENTS OF OTHER TRANSPLANTS
192 Kidney Diseases in Nonrenal Transplant Recipients
Robert B. Colvin, MD
196 Graft-vs.-Host Glomerulopathies
Anthony Chang, MD and Yael K. Heher, MD, MPH, FRCP(C)
DRUG TOXICITIES
198 Calcineurin Inhibitor Toxicity
Shane Meehan, MB, BCh
204 mTOR Inhibitor Toxicity
Lynn D. Cornell, MD
INFECTIONS
206 Acute Pyelonephritis
Neeraja Kambham, MD
214 Polyomavirus Nephritis
Anthony Chang, MD and Evan Farkash, MD, PhD
222 Adenovirus Infection
Anthony Chang, MD and R. Neal Smith, MD, PhD
224 Cytomegalovirus Infection
Anthony Chang, MD and R. Neal Smith, MD, PhD
226 Mucormycosis
Anthony Chang, MD
228 Histoplasmosis
Anthony Chang, MD
229 Candidiasis
Anthony Chang, MD
230 Cryptococcosis
Anthony Chang, MD
231 Aspergillosis
Anthony Chang, MD
232 Coccidioidomycosis
Anthony Chang, MD
233 Paracoccidioidomycosis
Anthony Chang, MD
234 Microsporidiosis
Robert B. Colvin, MD
236 Tuberculosis
Neeraja Kambham, MD
238 Malakoplakia
Neeraja Kambham, MD
242 Nocardiosis
Neeraja Kambham, MD
SECTION 5: LIVER TRANSPLANTATION
246 Pathologic Classification of Liver Allograft Diseases
John Hart, MD and Lindsay Alpert, MD
248 Gross Evaluation of Failed Native Liver
John Hart, MD and Lindsay Alpert, MD
252 Evaluation of Failed Liver Allograft
John Hart, MD and Lindsay Alpert, MD
254 Evaluation of the Donor Liver
John Hart, MD
258 History of Liver Transplantation
Anthony Chang, MD and John Hart, MD
POSTTRANSPLANT SURGICAL COMPLICATIONS
260 Preservation Injury
Hanlin L. Wang, MD, PhD
262 Hepatic Artery Thrombosis
Lisa Yerian, MD
264 Portal Vein Thrombosis
Lisa Yerian, MD
266 Bile Duct Stricture, Leak, Sludge, Biloma
Hanlin L. Wang, MD, PhD
268 Hepatic Venous Outflow Obstruction
Hanlin L. Wang, MD, PhD
272 Hyperperfusion Syndrome
Hanlin L. Wang, MD, PhD
ALLOGRAFT REJECTION
274 T-Cell-Mediated Rejection, Liver
Lisa Yerian, MD
278 Antibody-Mediated Rejection, Liver
Hanlin L. Wang, MD, PhD, Robert B. Colvin, MD, and
Richard Masia, MD, PhD
282 Chronic (Ductopenic) Rejection
Matthew M. Yeh, MD, PhD
RECURRENT DISEASES IN LIVER ALLOGRAFT
284 Recurrent Hepatitis B Virus
Lindsay Alpert, MD
286 Recurrent Hepatitis C Virus
Lindsay Alpert, MD
290 Fibrosing Cholestatic HBV or HCV Hepatitis
Lindsay Alpert, MD
292 Recurrent Autoimmune Hepatitis
Lindsay Alpert, MD
294 Recurrent Primary Biliary Cholangitis
Lindsay Alpert, MD
296 Recurrent Primary Sclerosing Cholangitis
Lindsay Alpert, MD
298 Recurrent Fatty Liver Disease
Lindsay Alpert, MD
INFECTIONS
300 Cytomegalovirus
Maria Westerhoff, MD and Joseph Ahn, MD, MS, FACG
302 Herpes Simplex Virus
Maria Westerhoff, MD and Joseph Ahn, MD, MS, FACG
304 Adenovirus, Liver
Maria Westerhoff, MD and Joseph Ahn, MD, MS, FACG
306 Hepatitis E Virus
Maria Westerhoff, MD and Joseph Ahn, MD, MS, FACG
308 Epstein-Barr Virus, Liver
Maria Westerhoff, MD and Joseph Ahn, MD, MS, FACG
312 Fungal Infections, Liver
Maria Westerhoff, MD and Joseph Ahn, MD, MS, FACG
LATE-GRAFT DYSFUNCTION
314 Plasma Cell-Rich Rejection
Lisa Yerian, MD
316 Graft-vs.-Host Disease, Liver
Lisa Yerian, MD
SECTION 6: HEART TRANSPLANTATION
320 Pathologic Classification of Cardiac Allograft Diseases
Aliya N. Husain, MD
322 Evaluation of Failed Native and Transplanted Heart
Jennifer Pogoriler, MD, PhD
324 History of Heart Transplantation
Aliya N. Husain, MD and Aarti Sharma, MD
EVALUATION OF EXPLANTED HEART
326 Ischemic Heart Disease
Aliya N. Husain, MD and Aarti Sharma, MD
330 Dilated Cardiomyopathy
Jennifer Pogoriler, MD, PhD
334 Hypertrophic Cardiomyopathy
Jennifer Pogoriler, MD, PhD and Aliya N. Husain, MD
338 Congenital Heart Disease
Jennifer Pogoriler, MD, PhD and Aliya N. Husain, MD
342 Sarcoidosis, Heart
Aliya N. Husain, MD and Aarti Sharma, MD
344 Arrhythmogenic Right Ventricular Cardiomyopathy
Jennifer Pogoriler, MD, PhD and Aliya N. Husain, MD
348 Other Causes of End-Stage Heart Disease
Jennifer Pogoriler, MD, PhD and Aliya N. Husain, MD
ALLOGRAFT REJECTION
354 Acute Cellular Rejection, Heart
Aliya N. Husain, MD and Jennifer Pogoriler, MD, PhD
358 Antibody-Mediated Rejection, Heart
Aliya N. Husain, MD and Aarti Sharma, MD
360 Chronic Allograft Vasculopathy, Heart
Aliya N. Husain, MD and Aarti Sharma, MD
NONINFECTIOUS LESIONS
362 Quilty Lesions
Aliya N. Husain, MD and Aarti Sharma, MD
364 Site of Previous Biopsy
Aliya N. Husain, MD and Vijayalakshmi
Ananthanarayanan, MD
INFECTIONS
366 Myocarditis
Jennifer Pogoriler, MD, PhD and Aliya N. Husain, MD
SECTION 7: LUNG TRANSPLANTATION
374 Pathologic Classification of Lung Allograft Diseases
Aliya N. Husain, MD and Aarti Sharma, MD
376 Examination of Native and Transplanted Lungs
Aliya N. Husain, MD
378 History of Lung Transplantation
Aliya N. Husain, MD and Aarti Sharma, MD
EVALUATION OF FAILED NATIVE LUNG
380 Emphysema
Aliya N. Husain, MD
382 Cystic Fibrosis
Aliya N. Husain, MD
384 Idiopathic Pulmonary Fibrosis
Aliya N. Husain, MD and Aarti Sharma, MD
386 Connective Tissue Disease-Associated Lung Disease
Ilyssa O. Gordon, MD, PhD and Aliya N. Husain, MD
388 Sarcoidosis, Lung
Aliya N. Husain, MD
390 Pulmonary Arterial Hypertension
Aliya N. Husain, MD and Aarti Sharma, MD
392 Other Causes of End-Stage Lung Disease
Aliya N. Husain, MD and Aarti Sharma, MD
SURGICAL COMPLICATIONS
396 Surgical Aspects and Complications, Lung
Aliya N. Husain, MD and Aarti Sharma, MD
ALLOGRAFT REJECTION
398 Pathologic Classification of Rejection
Aliya N. Husain, MD and Aarti Sharma, MD
400 Antibody-Mediated Rejection, Lung
Aliya N. Husain, MD and Ilyssa O. Gordon, MD, PhD
402 Acute Cellular Rejection, Grade A
Aliya N. Husain, MD
404 Acute Cellular Rejection, Grade B
Aliya N. Husain, MD
406 Chronic Allograft Dysfunction, Lung
Aliya N. Husain, MD
NONINFECTIOUS LESIONS
408 Organizing Pneumonia
Aliya N. Husain, MD
410 Microaspiration
Aliya N. Husain, MD
INFECTIONS
412 Bacterial Infections
Aliya N. Husain, MD and Ilyssa O. Gordon, MD, PhD
414 Viral Infections
Aliya N. Husain, MD and Aarti Sharma, MD
418 Fungal Infections, Lung
Aliya N. Husain, MD
SECTION 8: INTESTINAL TRANSPLANTATION
424 Pathologic Classification of Intestinal Allograft Diseases
Sarangarajan Ranganathan, MD
426 Indications and Evaluation of Explant
Sarangarajan Ranganathan, MD
430 Reperfusion Injury
Sarangarajan Ranganathan, MD
434 History of Intestinal and Multivisceral Transplantation
Sarangarajan Ranganathan, MD
ALLOGRAFT REJECTION/IMMUNOLOGICAL INJURY
436 Acute Antibody-Mediated Rejection, Intestine
Sarangarajan Ranganathan, MD
440 Acute Cellular Rejection, Intestine
Sarangarajan Ranganathan, MD
448 Chronic Rejection, Intestine
Sarangarajan Ranganathan, MD
452 Stomach Rejection
Sarangarajan Ranganathan, MD
456 Colon Rejection
Sarangarajan Ranganathan, MD
460 Graft-vs.-Host Disease, Intestine
Sarangarajan Ranganathan, MD
INFECTIONS
464 Bacterial and Fungal Infections
Sarangarajan Ranganathan, MD
468 Adenovirus, Intestine
Sarangarajan Ranganathan, MD
472 Rotavirus, Cytomegalovirus, and Herpes Simplex Virus
Sarangarajan Ranganathan, MD
476 Epstein-Barr Virus, Intestine
Sarangarajan Ranganathan, MD
SECTION 9: PANCREAS TRANSPLANTATION
484 Pathologic Classification of Pancreas Allograft Diseases
Surya V. Seshan, MD and Billie S. Fyfe, MD
486 Clinical Considerations in Pancreas Transplant Evaluation
Surya V. Seshan, MD and Billie S. Fyfe, MD
492 History of Pancreas Transplantation
Surya V. Seshan, MD and Billie S. Fyfe, MD
494 History of Islet Transplantation
Piotr Witkowski, MD, PhD
SURGICAL COMPLICATIONS
498 Surgical Aspects and Complications, Pancreas
Surya V. Seshan, MD and Billie S. Fyfe, MD
ALLOGRAF REJECTION
504 Acute Cellular Rejection, Pancreas
Surya V. Seshan, MD, Billie S. Fyfe, MD, and Erika R. Bracamonte, MD
508 Antibody-Mediated Rejection, Pancreas
Surya V. Seshan, MD and Billie S. Fyfe, MD
512 Chronic Allograft Rejection/Graft Sclerosis
Surya V. Seshan, MD, Billie S. Fyfe, MD, and Erika R. Bracamonte, MD
GRAFT DYSFUNCTION
514 Recurrent Diabetes Mellitus
Surya V. Seshan, MD and Billie S. Fyfe, MD
518 Islet Cell Toxicity and Islet Amyloid Deposition
Surya V. Seshan, MD and Billie S. Fyfe, MD
INFECTIONS
520 Intraabdominal and Opportunistic Infections
Surya V. Seshan, MD and Billie S. Fyfe, MD
SECTION 10: VASCULARIZED COMPOSITE ALLOTRANSPLANTATION
528 History of Vascularized Composite Allotransplantation
Linda Cendales, MD
ALLOGRAFT REJECTION
530 Acute T-Cell- and Antibody-Mediated Rejection
A. Brad Farris, III, MD, MBA, Ivy A. Rosales, MD, and Robert B. Colvin, MD
538 Chronic Rejection
A. Brad Farris, III, MD, MBA, Robert B. Colvin, MD, and Ivy A. Rosales, MD
SECTION 11: POSTTRANSPLANT NEOPLASTIC DISORDERS
542 Posttransplant Lymphoproliferative Diseases
A. Brad Farris, III, MD, MBA